In summary, multiplex ADAP assay could be an ideal tool for type 1 diabetes risk testing due to its sample-sparing nature (4μL), non-radioactiveness, compatibility with widely available real-time qPCR instruments and favorable risk prediction capability. This evidence concerns the gene FYB1 and type 1 diabetes mellitus.